Evia Bio Announces Availability of GMP-Grade DMSO-Free Cryopreservation Media for Mesenchymal Stromal Cells
The medium is produced by Teknova and can be ordered through the company’s website for direct shipment.

Key Points
- Evia Bio announced that GMP-grade CellShield MSC, a DMSO-free cryopreservation medium for mesenchymal stromal cells, is available for purchase and shipment.
- The CellShield line includes a controlled-rate freezing program that the company says is designed to optimize viability, recovery, and functionality.
- The medium is manufactured by Teknova and can be ordered through Evia Bio’s website.
Evia Bio, a provider of non-dimethyl sulfoxide (DMSO) cryopreservation solutions for the cell therapy and in vitro fertilization industries, announced that GMP-grade CellShield MSC, a DMSO-free cryopreservation medium for mesenchymal stromal cells, is now available for product shipment to customers.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
The CellShield product line includes a controlled-rate freezing program designed to optimize viability, recovery, and functionality, according to the company. GMP-grade CellShield MSC is available for purchase via the Evia Bio website and direct shipment from the manufacturer.
“As a leader in the development of non-DMSO cryopreservation solutions, we are thrilled to introduce the GMP grade of CellShield MSC, which was specifically designed to help cell therapy developers protect and maintain MSC integrity as well as improve patient safety at the point of care,” said Jeffrey Allen, Evia Bio’s Chairman and Chief Executive Officer.
CellShield MSC is manufactured by Teknova, a provider of critical reagents for the development and commercialization of emerging therapies, vaccines, and molecular diagnostics.
Evia Bio is a life science innovation company providing DMSO-free cryopreservation products and solutions developed by cryobiologist Allison Hubel, PhD. The company partners with cell therapy companies looking to advance their products to clinical trials and commercialization.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
Kangstem Biotech Reports Positive Phase 2a Results for Stem Cell Knee Osteoarthritis Therapy
CellFiber Opens First International Subsidiary in Philadelphia to Support Cell and Gene Therapy Development
Porton Advanced Announces FDA Acceptance of Drug Master File for Umbilical Cord Stem Cell-Derived Exosomes
INmune Bio and Uniphar Team Up to Support International Access to Umbilical Cord-Derived Cell Therapy for RDEB
ABEC Launches ATB-2100 Advanced Therapy Bioreactor for Cell and Gene Therapy Manufacturing
Pluri and ZEO ScientifiX Team Up to Expand U.S. Regenerative Medicine Manufacturing and Commercialization
Darwin Biotechnology Enrolls First Patient in Phase II Trial of MSC-Derived Protein Complex for Persistent Neurological Deficits After Ischemic Stroke
Made Scientific and CARR Biosystems Partner on Single-Use Centrifugation for Cell Therapy Manufacturing







